Literature DB >> 19709084

A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases.

Emilie Létocart1, Gérald Le Gac, Silvia Majore, Chandran Ka, Francesca C Radio, Isabelle Gourlaouen, Carmelilia De Bernardo, Claude Férec, Paola Grammatico.   

Abstract

Ferroportin-related iron overload disease differs from haemochromatosis in that it has a dominant mode of inheritance and is usually associated with macrophage iron sequestration. However, it is thought that mutations with opposite effects on protein functions, i.e. loss-of-function versus gain-of-function mutations, are responsible for variable phenotype presentations. The present study investigated the functional relevance of a novel ferroportin variant: the c.1502 A>G transition, which changes amino acid 501 from tyrosine to cysteine (p.Y501C). This novel variant was identified in a pedigree originating from Central Italy and, although an intra-familial phenotype heterogeneity was observed, it co-segregated with an iron overload picture similar to that of the HFE-related typical haemochromatosis. In cultured cells, the p.Y501C mutant protein reached the plasma membrane and retained a full iron export ability. By contrast, it was resistant to inhibition by hepcidin. These findings confirm that certain ferroportin mutations compromise the activity of hepcidin in iron homeostasis, mimicking hepcidin deficiency as described in all types of hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709084     DOI: 10.1111/j.1365-2141.2009.07834.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress.

Authors:  De-Liang Zhang; Manik C Ghosh; Hayden Ollivierre; Yan Li; Tracey A Rouault
Journal:  Blood       Date:  2018-09-13       Impact factor: 22.113

2.  A male patient with ferroportin disease B and a female patient with iron overload similar to ferroportin disease B.

Authors:  Tetsuji Yamashita; Natsuko Morotomi; Tetsuro Sohda; Hisao Hayashi; Naohiko Yoshida; Keiko Ochi; Izumi Ohkura; Mika Karita; Hiroko Fujiwara; Haruhiko Yamashita; Ai Hattori; Yasuaki Tatsumi
Journal:  Clin J Gastroenterol       Date:  2014-04-19

3.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

Review 4.  Ceruloplasmin-ferroportin system of iron traffic in vertebrates.

Authors:  Giovanni Musci; Fabio Polticelli; Maria Carmela Bonaccorsi di Patti
Journal:  World J Biol Chem       Date:  2014-05-26

5.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

6.  Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.

Authors:  Gautam Rishi; Eriza S Secondes; Daniel F Wallace; V Nathan Subramaniam
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

7.  A 10-year Follow-up Study of a Japanese Family with Ferroportin Disease A: Mild Iron Overload with Mild Hyperferritinemia Co-occurring with Hyperhepcidinemia May Be Benign.

Authors:  Hisao Hayashi; Motoyoshi Yano; Naohito Urawa; Akane Mizutani; Shima Hamaoka; Jun Araki; Yuji Kojima; Yutaka Naito; Ayako Kato; Yasuaki Tatsumi; Koichi Kato
Journal:  Intern Med       Date:  2018-05-18       Impact factor: 1.271

8.  TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia.

Authors:  Stefan Weiler; Manfred Nairz
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

Review 9.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

Review 10.  Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.

Authors:  L Tom Vlasveld; Roel Janssen; Edouard Bardou-Jacquet; Hanka Venselaar; Houda Hamdi-Roze; Hal Drakesmith; Dorine W Swinkels
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.